Updates are available Correction dated 2019-03-21
Click to view Correction: https://doi.org/10.1186/s40560-019-0370-8
-
Authors
Mizutani, Takashi
Umemoto, Norio https://orcid.org/0000-0002-0409-8610
Taniguchi, Toshio
Ishii, Hideki
Hiramatsu, Yuri
Arata, Koji
Takuya, Horagaito
Inoue, Sho
Sugiura, Tsuyoshi
Asai, Toru
Yamada, Michiharu
Murohara, Toyoaki
Shimizu, Kiyokazu
- License Information
-
More Information
Article History
Received: 28 February 2018
Accepted: 24 May 2018
First Online: 1 June 2018
Change Date: 21 March 2019
Change Type: Correction
Change Details: In the original publication of this article [1], the values of PH in the Table 4 are wrong.
Ethics approval and consent to participate
: This study was approved by the clinical trial review committee of the Ichinomiya Municipal Hospital. As this was a retrospective study, the need for informed consent was waived.
: H.I. received lecture fees from Astellas Pharma Inc., Daiichi-Sankyo Pharma Inc., and MSD K.K. T. M. received lecture fees from Bayel Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Kowa Co., Ltd., MSD K.K., Mitsubishi Tanabe Pharma Co., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Pfizer Japan Inc., Sanofi-aventis K.K., and Takeda Pharmaceutical Co., Ltd.T.M. received unrestricted research grant from the Department of Cardiology, Nagoya University Graduate School of Medicine from Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Kowa Co., Ltd., MSD K.K., Mitsubishi Tanabe Pharma Co., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Otsuka Pharma Ltd., Pfizer Japan Inc., Sanofi-aventis K.K., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd.The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
